What cholesterol medication is safe to take with Entresto (sacubitril/valsartan)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cholesterol Medications Safe to Take with Entresto (Sacubitril/Valsartan)

Rosuvastatin is the safest cholesterol medication to take with Entresto (sacubitril/valsartan) due to its lower risk of drug-drug interactions compared to other statins. 1

Drug Interaction Concerns with Entresto

  • Sacubitril, a component of Entresto, can inhibit the excretion of certain statins, potentially increasing serum statin concentrations and the risk of muscle-related toxicity 1
  • Life-threatening rhabdomyolysis has been reported with the co-administration of atorvastatin and sacubitril/valsartan, highlighting the importance of careful selection of cholesterol medications 1
  • Entresto is primarily used in heart failure with reduced ejection fraction, where cholesterol management is often also needed 2, 3

Recommended Cholesterol Medications with Entresto

Preferred Options:

  • Rosuvastatin: Has less drug-drug interaction with sacubitril, making it a safer choice when combined with Entresto 1
  • Pravastatin: Less dependent on CYP3A4 metabolism, which reduces potential interactions with Entresto 3
  • Fluvastatin: Has different metabolic pathways that make it less likely to interact significantly with Entresto 3

Use with Caution:

  • Atorvastatin: If used with Entresto, should be started at a lower dose (20 mg daily) and titrated cautiously with regular monitoring of creatine kinase (CK), liver function, and renal function 1
  • Ezetimibe: Can be considered as an add-on or alternative therapy, particularly in patients who cannot tolerate statins 3

Avoid:

  • Simvastatin and Lovastatin: These are extensively metabolized by CYP3A4 and have higher risk of interactions with medications that affect this pathway 3
  • Pitavastatin: Should be avoided due to potential interactions 3

Monitoring Recommendations

  • Check baseline liver function tests and CK levels before initiating combination therapy 3
  • Monitor for symptoms of muscle toxicity (myalgia, weakness, dark urine) 1
  • Perform follow-up laboratory testing 4-12 weeks after initiation and periodically thereafter 3
  • Assess renal function regularly, as both Entresto and certain statins can affect kidney function 4

Special Considerations

  • For patients at very high cardiovascular risk who require intensive lipid lowering, consider PCSK9 inhibitors (evolocumab, alirocumab) which work through different mechanisms and may have fewer interactions with Entresto 3, 5
  • Bile acid sequestrants (colesevelam, cholestyramine) could be alternative options for patients who cannot tolerate statins, but should be taken at least 2 hours before or 4 hours after Entresto to avoid interference with absorption 5
  • In patients with diabetes and heart failure, careful selection of lipid-lowering therapy is particularly important 3

Clinical Pitfalls to Avoid

  • Never start high-dose statin therapy immediately when combining with Entresto; always begin with lower doses and titrate gradually 1
  • Do not ignore symptoms of muscle pain in patients on combination therapy, as this could be an early sign of rhabdomyolysis 1
  • Avoid assuming that all statins carry the same risk when combined with Entresto; their interaction potential varies significantly 3
  • Regular monitoring is essential, as adverse effects may develop even after months of stable combination therapy 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Protective effect of sacubitril/valsartan (Entresto) on kidney function and filtration barrier injury in a porcine model of partial nephrectomy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023

Guideline

Non-Statin Cholesterol Medications Beyond Ezetimibe and Fenofibrate

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.